Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of DCR-AUD in Healthy Volunteers
NCT05021640Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DCR-AUD in alcohol use disorder (AUD) (5 arms), sponsored by Novo Nordisk. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) at 24 weeks, Number of Participants With Change From Baseline in Clinically Significant Abnormal Vital Signs at 24 weeks and 2 more. Started Sep 2021; status: completed.
02
Drugs
DCR-AUD
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT05021640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05021640.